Ask a Question

Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others

* Required field

Your Email Address *

Please enter a valid email address.

Choose a Topic *

Tell us your question and any additional information *

Please enter all required fields.

Please Log In/Join Now first, and then use this function!

Find a Clinical Trial

Covid-19 (Coronavirus) Message for Patients

Note: As a result of the current COVID-19 (Coronavirus) restrictions, research sites may incorrectly be listed as recruiting or be delayed in responding to patient inquiries due to possible closures. It is suggested that interested patients awaiting a response or current study patients can contact the research site at the phone number provided to ask about study status or confirm scheduled appointments before arriving. Read more about BMS's response to COVID-19 at www.BMS.com.

Researching Blood Cancer

Blood cancers form in the bone marrow where blood is made, or in the lymphatic system, which protects us from infections.

Jump to Studies

Leukemia | Lymphoma | Multiple Myeloma

Blood Cancer Clinical Trials

We are currently investigating experimental medications for Multiple Myeloma, Lymphoma and Leukemia.

Multiple Myeloma is a type of blood cancer which forms in plasma cells.
Lymphomas are blood cancers that target the immune system.
Leukemia is a cancer of the blood and bone marrow caused by too many white blood cells, leukemia takes on several forms and can occur in both children and adults.

Thank you for Considering a Clinical Trial

Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).

Here are some options for you to find more information:

Browse the trials available on your own and Click on View Trial Details for more information, including locations that are recruiting patients.
- or -
Let us help you find a trial: Pre-Screen Now and answer a few questions to determine if there is a trial that might be right for you.

Leukemia Trials

CV185-155

Recruiting

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

View Trial Details

017004

Recruiting

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-90009-AML-002

Recruiting

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

View Trial Details

Lymphoma Trials

CV185-155

Recruiting

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

View Trial Details

CA209-744

Recruiting

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

View Trial Details

JCAR017-FOL-001

Recruiting

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

017004

Recruiting

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-220-NHL-001

Recruiting

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

View Trial Details

Multiple Myeloma Trials

CC-220-MM-001

Recruiting

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

View Trial Details

CC-92480-MM-001

Recruiting

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

View Trial Details

CC-93269-MM-001

Recruiting

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma

View Trial Details

BB2121-MM-002

Recruiting

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

View Trial Details

BB2121-MM-003

Recruiting

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

View Trial Details

CC-92480-MM-002

Recruiting

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

View Trial Details

CC-99712-MM-001

Recruiting

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

View Trial Details

BB2121-MM-004

Recruiting

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

View Trial Details

CC-98633-MM-001

Recruiting

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

CC-95266-MM-001

Recruiting

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Juno Therapeutics and Celgene are wholly owned subsidiaries of Bristol-Myers Squibb Company

View Trial Details

NDS-MM-004

Recruiting

A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM

View Trial Details

Get updates on clinical trials

Get notified when new studies open that might be right for you

What are you thankful for?

"I am thankful that I had friends & family to lean on – I don’t like being vulnerable, but being so was freeing in the end." ...

Silver Linings, Breast Cancer - Survivor

View Story

"I am thankful that I had friends & family to lean on – I don’t like being vulnerable, but being so was freeing in the end." ...

Silver Linings, Breast Cancer - Survivor

View Story

"I noticed a red spot on my shoulder and didn't think too much about it, but after a few more days it didn't change. Nancy recommended that I probably ought to get it checked"

Larry and Nancy, Melanoma

View Story

"I noticed a red spot on my shoulder and didn't think too much about it, but after a few more days it didn't change. Nancy recommended that I probably ought to get it checked"

Larry and Nancy, Melanoma

View Story

"They want you to be as safe as possible. So as soon as they notice something is off, they will tell you. And you have the option of saying, 'OK, I'm out.'"

Lucy, Rheumatoid Arthritis

View Story

"They want you to be as safe as possible. So as soon as they notice something is off, they will tell you. And you have the option of saying, 'OK, I'm out.'"

Lucy, Rheumatoid Arthritis

View Story

"The medical oncologist did lay out exactly what was going to happen if I did go through this clinical trial, so there weren't any surprises"

Tolley, Melanoma

View Story

"The medical oncologist did lay out exactly what was going to happen if I did go through this clinical trial, so there weren't any surprises"

Tolley, Melanoma

View Story

All Stories

Explore Blood Cancer Resources

More About Blood Cancer

By the numbers - More than 1 million new blood cancer cases are expected to be diagnosed globally in 2020, accounting for approximately 6% of all new cancer cases.

Learn More

Leukemia Statistics

Did You Know? Video Series

Bristol Myers Squibb is not affiliated with the creators of this content. The information provided here is for informational purposes only and is not meant to replace a physician's medical advice or imply endorsement. Content in this video may speak to medical topics that are not necessarily related to clinical trials.

Source: NIH (National Institute of Heath) – used with permission 2:53

SELECTED SUPPORT ORGANIZATIONS AND DISEASE INFORMATION

Bristol Myers Squibb is not affiliated with nor endorses any of the listed organizations. The information/links provided by Bristol Myers Squibb are meant for informational purposes only and are not meant to replace a physician's medical advice or imply endorsement. This is not an exhaustive list of resources for this condition. There may be others that you may wish to explore.

National Cancer Institute Multiple Myeloma Overview

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -

Call 855-907-3286 or email clinical.trials@bms.com